Ruxolitinib: A restorative of COVID-19

Abstract

Despite mass level vaccinations and the launch of several repurposed drugs, the recently emerged SARS CoV-2 Omicron (B.1.1.529) is a variant of concern. New drugs must be discovered with artificial intelligence (AI) assistance. Artificial intelligence (AI) enabled drug repurposing reduces the time and costs of drug discovery. Ruxolitinib (formerly known as INCB018424; Jakavi; Jakafi) is an oral inhibitor of JAK 1 & 2. Ruxolitinib has been approved to treat primary myelofibrosis, polycythemia vera, and hemophagocytic lymphohistiocytosis by the Food and Drug Administration and European Medicines Agency. The analysis of ruxolitinib is done via the CoV-DrugX pipeline. We find that the Ruxolitinib has a 75% probability of being considered a COVID-19 repurposed drug with the help of the CoV-DrugX pipeline. In addition, there is a clinical trial assessing the safety and efficacy of ruxolitinib. Therefore, we believe that Ruxolitinib could be a potent drug against the treatment of COVID-19.